Plain-English translation of NCT04523428 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether venetoclax and acalabrutinib — two targeted cancer medications — can be used together to treat chronic lymphocytic leukemia (a blood cancer) in patients whose cancer has come back after an initial treatment. The study is looking at whether this combination can help patients achieve deep remissions and possibly stop treatment eventually.
When patients with this type of blood cancer were first treated with venetoclax and other antibody drugs, many went into remission. However, some patients' cancer came back, and doctors have not yet confirmed whether retreating with this medication is effective. This trial aims to prove whether this approach actually works for patients facing a recurrence.
You likely qualify if…
You likely don't qualify if…
You would start by taking one of the medications alone for two cycles (about 2 months), then gradually add the second medication while continuing the first. After that, you would take both medications together for up to 24 cycles (about 2 years total). Throughout the trial, you would visit the clinic regularly for blood tests, check-ups, and monitoring to see how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Belgium
Denmark
Netherlands